0:46:08 · Matthias Agblom, Nordea · Pipeline value
Is the 2027 peak-year revenue potential spread evenly across the key readouts, and will cancer vaccines be partnered or built in-house?
Management said no single readout, including AVANZAR, is make-or-break, and that cancer vaccines are being developed internally for now. — Pascal Soriot
0:49:14 · Simon Becker, Rothschild · Restructuring, B7H4 ADC
What does the restructuring programme involve, is the $2 billion cash, and how does puxitatug samrotecan differ in the crowded B7H4 space?
The programme realigns investment across units, such as the clinical trial footprint and cell therapy skills, and the $2 billion is mostly cash. Puxitatug samrotecan has broader B7H4 expression than folate receptor alpha, a stable linker and lower bone-marrow toxicity. — Aradhana Sarin, Susan Galbraith
0:53:31 · Sachin Jan, Bank of America · R&D, post-2030 growth
Will R&D growth accelerate next year, and when will management quantify growth beyond 2030?
The CFO declined to give 2027 guidance before February but flagged continued launch investment and headwinds; the CEO said a post-2030 target is undecided and too early. — Aradhana Sarin, Pascal Soriot
0:58:58 · Steve Scala, Cowen · Imfinzi SC, China
Is there a subcutaneous opportunity for Imfinzi, and is China's biopharma push a headwind or tailwind?
Subcutaneous Imfinzi is progressing and is expected to launch before intravenous loss of exclusivity; China is seen as both tailwind and headwind, hopefully net positive given AstraZeneca's position. — Dave Fredrickson, Pascal Soriot
1:03:00 · Richard Vosser, JPM · Tagrisso, saruparib
How should Tagrisso grow from here, and what does the Lynparza first-line ovarian setback mean for saruparib?
Tagrisso should keep growing through FLAURA2, TROPION-Lung14 and 15 and the Orpathys combinations. Saruparib is a PARP1-selective inhibitor with strong early prostate data and a trial designed to be powered for both HRRm and non-HRRm patients. — Dave Fredrickson, Susan Galbraith
1:08:37 · Graham Perry, Citi · Pipeline value, Etcamah
Has internal pipeline value risen or fallen after the failures, and can Etcamah pricing hold in adjuvant breast cancer?
Management said net pipeline value has gone up despite the two failures, and said Etcamah early-breast-cancer pricing will be decided after CAMBRIA-1 results. — Pascal Soriot, Dave Fredrickson
1:13:35 · Rajan Sharma, Goldman Sachs · 2027 launches
How meaningful will Baxfendy, Etcamah and tozorakimab be next year, and what is the margin impact of the launches?
Baxfendy has 12,000 new patient starts with Part D coverage expected in 2028, and Etcamah is seen as a blockbuster. Launch investment starts 18-24 months early and breakeven often takes several years. — Ruud Dobber, Dave Fredrickson, Marc Dunoyer, Aradhana Sarin
1:21:10 · Analyst, Morgan Stanley · CAMBRIA-1
Which patient pool will feed CAMBRIA-1: those previously on CDK4/6 plus aromatase inhibitor, or aromatase inhibitor alone?
CAMBRIA-1 is a switch design covering the prevalent pool of patients after two to five years of adjuvant therapy, whether or not they had CDK4/6 inhibitors. — Susan Galbraith, Dave Fredrickson
1:24:07 · Tranguin, RBC · CV combinations
How are the oral cardiovascular combinations differentiated, and is a GLP-1 plus PCSK9 combination still considered?
Laroprovstat plus rosuvastatin and elecoglipron plus dapagliflozin each address interrelated disease drivers, and a GLP-1 plus PCSK9 combination is under consideration. — Sharon Barr, Ruud Dobber
1:28:09 · James Gordon, Barclays · Investment, margins
Which new technologies need the most investment, and can the cost programme support margin expansion?
Technologies are at different stages, with cell therapy getting the most spend now. Management will try to protect operating margin but gave no new margin guidance. — Pascal Soriot, Aradhana Sarin
1:32:26 · Peter Verdult, BNP Paribas · Europe pricing, MFN
Are European leaders likely to reward innovation better, and how was Baxfendy priced ex-US given MFN?
Management sees Japan as encouraging and Europe as showing early green shoots; Baxfendy is getting good prices in the Middle East. — Pascal Soriot, Ruud Dobber
1:36:58 · Simas Fernandez, Guggenheim · Reinvestment, underappreciated areas
Will restructuring savings be recycled into R&D, and where is AstraZeneca underappreciated?
Savings will be reinvested and no long-term margin guidance will be given; the CEO cited weight management and cell therapy as areas where AstraZeneca is underappreciated. — Aradhana Sarin, Pascal Soriot
1:41:49 · Michael Luchten · Restructuring timing
Why launch the restructuring programme now?
Management cited Farxiga loss of exclusivity, pricing and launch pressures, trial-footprint changes and AI embedded in processes, and said planning began at the start of the year. — Aradhana Sarin, Pascal Soriot